Memo Therapeutics AG

Memo Therapeutics AG (MTx) is a late-stage biotech company translating unique human immune responses into superior medicines through the development of best-in-class antibodies to treat viral infections and cancer. The Companys lead program, Potravitug, is in Phase II development targeting BK viremia (BKV) in kidney transplant recipients, an infection which can result in decreased kidney functionality and longevity and reduced patient survival. Potravitug has the potential to become the best and first-in-class BKV disease-modifying therapy for kidney transplant patients. Alongside Potravitug, MTx is focused on discovering novel antibody-target pairs for oncology based on tumor infiltrating B-cells derived leveraging tertiary lymphoid...

Therapeutic antibodies,infectious disease,human antibodies,antibody repertoire,antibodyome,high throughput,single b cell,and antibody discovery

Memo therapeutics ag operates in the Biotechnology research industry.

Memo therapeutics ag's revenue is 11m - 100m

Memo therapeutics ag has 11 - 50 employees.